Core Viewpoint - The announcement highlights that Zhonghui Biotech-B (02627.HK) has received approval from the National Medical Products Administration for its trivalent influenza virus subunit vaccine, making it the first and only vaccine approved for all age groups in China [1] Group 1: Product Approval - The trivalent influenza virus subunit vaccine is now approved for all age groups, marking a significant milestone for the company [1] - This vaccine is the first and only one in China that has been approved for the entire population and all dosage levels [1] Group 2: Product Advantages - The vaccine represents a major upgrade over traditional virus split vaccines, offering comprehensive protection [1] - It features high purity of antigen components and a lower risk of adverse reactions [1]
中慧生物-B(02627.HK)：三价流感病毒亚单位疫苗的上市申请获国家药监局批准